Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake

Hedge fund increases holdings in biotech company by over 700%

Mar. 13, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Quadrature Capital Ltd, a hedge fund, significantly increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter of 2025. The fund added 131,995 shares, raising its total holdings to 149,908 shares, a 736.9% increase from the previous quarter.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases, particularly cystic fibrosis. The substantial increase in Quadrature Capital's position suggests the hedge fund sees significant potential in Vertex's pipeline and future growth prospects.

The details

According to a recent 13F filing with the Securities and Exchange Commission, Quadrature Capital Ltd acquired an additional 131,995 shares of Vertex Pharmaceuticals during the third quarter. This brought the fund's total holdings in the biotech company to 149,908 shares, worth approximately $58.7 million at the end of the quarter.

  • Quadrature Capital Ltd increased its Vertex Pharmaceuticals holdings in the third quarter of 2025.

The players

Quadrature Capital Ltd

A hedge fund that significantly increased its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Quadrature Capital's substantial investment in Vertex Pharmaceuticals suggests the hedge fund sees strong growth potential in the biotech company's pipeline and future prospects. This could signal increased investor confidence in Vertex's ability to continue its success in developing innovative treatments for serious diseases.